0001144204-19-040629.txt : 20190819 0001144204-19-040629.hdr.sgml : 20190819 20190819160145 ACCESSION NUMBER: 0001144204-19-040629 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190815 FILED AS OF DATE: 20190819 DATE AS OF CHANGE: 20190819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chan Phillip P. CENTRAL INDEX KEY: 0001442786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 191036451 MAIL ADDRESS: STREET 1: 1001 BRIGGS ROAD STREET 2: SUITE 280 CITY: MOUNT LAUREL STATE: NJ ZIP: 08054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 4 1 tv527919_4.xml OWNERSHIP DOCUMENT X0306 4 2019-08-15 0 0001175151 Cytosorbents Corp CTSO 0001442786 Chan Phillip P. C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION NJ 08852 1 1 0 0 President and CEO Common Stock 2019-08-15 4 M 0 75000 3.45 A 641188 D Stock Option (right to buy) 3.45 2019-08-15 4 M 0 75000 0 D 2020-05-05 Common Stock 75000 14100 D Includes: (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan as follows: (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (ii) the following RSUs subject to vesting in three equal annual installments with the first of such vesting beginning on the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 40,000 RSUs granted on July 22, 2019 which are unvested as of the date hereof, (b) 3,667 RSUs granted on March 4, 2019 which are unvested as of the date hereof, and (c) 14,334 RSUs granted on February 28, 2018 which are unvested as of the date hereof; and (iii) 367,187 shares of common stock owned by the reporting person, inclusive of the 75,000 shares of common stock reported on this Form 4. On May 5, 2010 the reporting person was granted an option to purchase a total of 134,000 shares of common stock (after giving effect to the issuer's twenty-five-for-one reverse split) which was to vest at the discretion of the issuer's Board of Directors based on satisfying certain criteria including, but not limited to, timely completion of the sepsis trial, raising capital for the issuer, and partnering and business development. The issuer's Board of Directors subsequently determined that approximately two-thirds of such performance criteria was achieved, resulting in vesting of 89,100 shares underlying the option. /s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan 2019-08-19